Alice Aarnink
YOU?
Author Swipe
View article: The Novel <i>HLA‐DQA1*05:01:14</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The Novel <i>HLA‐DQA1*05:01:14</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The novel allele HLA‐DQA1*05:01:14 differs from HLA‐DQA1*05:01:01:01 by one synonymous nucleotide substitution in exon 3.
View article: The Novel <scp> <i>HLA‐C*07:1088</i> </scp> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The Novel <span> <i>HLA‐C*07:1088</i> </span> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The novel allele HLA‐C*07:1088 differs from HLAC*07:01:01:01 by one non‐synonymous nucleotide substitution in exon 3.
View article: The Novel <i>HLA‐DQB1*06:02:60</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The Novel <i>HLA‐DQB1*06:02:60</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The novel allele HLA‐DQB1*06:02:60 differs from HLA‐DQB1*06:02:01:01 by one synonymous nucleotide substitution in exon 2.
View article: The Novel <i>HLA‐DQB1*03:01:59</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The Novel <i>HLA‐DQB1*03:01:59</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The novel allele HLA‐DQB1*03:01:59 differs from DQB1*03:01:01:01 by one synonymous nucleotide substitution in exon 2.
View article: The New <i>HLA‐C*07:1130N</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The New <i>HLA‐C*07:1130N</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The new allele HLA‐C*07:1130N differs from HLA‐C*07:02:01:01 by one nonsense nucleotide substitution in exon 3.
View article: The New <i>HLA‐B*38:114</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The New <i>HLA‐B*38:114</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The new allele HLA‐B*38:114 differs from HLA‐B*38:32 by three nucleotide substitutions in exon 3.
View article: The New <i>HLA‐C*15:275</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The New <i>HLA‐C*15:275</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The new allele HLA‐C*15:275 differs from HLA‐C*15:02:01:01 by one non‐synonymous nucleotide substitution in exon 3.
View article: The Novel <i>HLA‐DRB1*13:348</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The Novel <i>HLA‐DRB1*13:348</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The novel allele HLA‐DRB1*13:348 differs from HLA‐DRB1*13:02:01:01 by one non‐synonymous nucleotide substitution in exon 2.
View article: The Novel <i>HLA‐C*07:1102</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques
The Novel <i>HLA‐C*07:1102</i> Allele Characterised by Two Different Sequencing‐Based Typing Techniques Open
The novel allele HLA‐C*07:1102 differs from HLA‐C*07:02:01:01 by one non‐synonymous nucleotide substitution in exon 2.
View article: Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin (<scp>ATLG</scp>) vs. Anti‐Thymocyte Globulin (<scp>ATG</scp>) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study
Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin (<span>ATLG</span>) vs. Anti‐Thymocyte Globulin (<span>ATG</span>) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study Open
Both anti‐T‐lymphocyte globulin (ATLG‐Grafalon) and anti‐thymocyte globulin (ATG‐Thymoglobulin) prevent acute and chronic graft‐versus‐host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Despite distin…
View article: Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial
Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial Open
Background The COVID-19 pandemic caused a wave of acute respiratory distress syndrome (ARDS) with a high in-hospital mortality, especially in patients requiring invasive mechanical ventilation. Wharton Jelly-derived Mesenchymal Stromal Cel…
View article: The novel <i>HLA</i>‐<i>C</i>*<i>07</i>:<i>1058</i> allele characterised by two different sequencing‐based typing techniques
The novel <i>HLA</i>‐<i>C</i>*<i>07</i>:<i>1058</i> allele characterised by two different sequencing‐based typing techniques Open
The novel allele HLA ‐ C * 07 : 1058 differs from HLA ‐ C * 07 : 02 : 01 : 01 by one non‐synonymous nucleotide substitution in exon 4.
View article: The novel <i>HLA‐B*53:01:30</i> allele characterised by two different sequencing‐based typing techniques
The novel <i>HLA‐B*53:01:30</i> allele characterised by two different sequencing‐based typing techniques Open
The novel allele HLA‐B*53:01:30 differs from HLA‐B*53:01:01:01 by one synonymous nucleotide substitution in exon 3.
View article: The novel <i>HLA‐B*44:369</i> allele characterised by two different sequencing‐based typing techniques
The novel <i>HLA‐B*44:369</i> allele characterised by two different sequencing‐based typing techniques Open
The novel allele HLA‐B*44:369 differs from HLA‐B*44:02:01:01 by one non‐synonymous nucleotide substitution in exon 3.
View article: Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation Open
View article: The novel <i><scp>HLA‐B</scp>*14:118</i> allele characterized by two different sequencing‐based typing techniques
The novel <i><span>HLA‐B</span>*14:118</i> allele characterized by two different sequencing‐based typing techniques Open
HLA‐B*14:118 differs from HLA‐B*14:93 by two non‐synonymous and one synonymous nucleotide substitution in exon 2.
View article: The novel <i>HLA‐A*11:443</i> allele characterised by two different sequencing‐based typing techniques
The novel <i>HLA‐A*11:443</i> allele characterised by two different sequencing‐based typing techniques Open
The novel allele HLA‐A*11:443 differs from HLA‐A*11:01:01:01 by one non‐synonymous nucleotide substitution in exon 2.
View article: Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation Open
Graft-versus-leukemia (GvL) reactions are responsible for the effectiveness of allogeneic hematopoietic cell transplantation as a treatment modality for myeloid neoplasia, whereby donor T- effector cells recognize leukemia neoantigens. How…
View article: The novel <i>HLA</i>‐<i>B</i>*<i>56</i>:<i>91</i> allele characterised by three different sequencing‐based typing techniques
The novel <i>HLA</i>‐<i>B</i>*<i>56</i>:<i>91</i> allele characterised by three different sequencing‐based typing techniques Open
The novel allele HLA ‐ B * 56 : 91 differs from HLA ‐ B * 56 : 33 by one non‐synonymous nucleotide substitution in exon 2.
View article: The novel <i>HLA‐DRB1*16:71</i> allele characterised by two different sequencing‐based typing techniques
The novel <i>HLA‐DRB1*16:71</i> allele characterised by two different sequencing‐based typing techniques Open
The novel allele HLA‐DRB1*16:71 differs from HLA‐DRB1*16:01:01:01 by one non‐synonymous nucleotide substitution in exon 2.
View article: The novel <i>HLA‐DRB5*02:35</i> allele characterized by two different sequencing‐based typing techniques
The novel <i>HLA‐DRB5*02:35</i> allele characterized by two different sequencing‐based typing techniques Open
The novel allele HLA‐DRB5*02:35 differs from HLA‐DRB5*02:02:01 by one non‐synonymous nucleotide substitution in exon 2.
View article: Comparison of NK alloreactivity prediction models based on KIR-MHC interactions in haematopoietic stem cell transplantation
Comparison of NK alloreactivity prediction models based on KIR-MHC interactions in haematopoietic stem cell transplantation Open
The biological processes underlying NK cell alloreactivity in haematopoietic stem cell transplantation (HSCT) remain unclear. Many different models to predict NK alloreactivity through KIR and MHC genotyping exist, raising ambiguities in i…
View article: KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection
KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection Open
Allogeneic hematopoietic stem cell transplantation (aHSCT) is a lifesaving therapy for hematological malignancies. For years, a fully matched HLA donor was a requisite for the procedure. However, new immunosuppressive strategies have enabl…